scholarly journals Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes

Cureus ◽  
2021 ◽  
Author(s):  
Sarunporn Kamolvisit ◽  
Supphamat Chirnaksorn ◽  
Hataikarn Nimitphong ◽  
Somnuek Sungkanuparph
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
People Living With Hiv ◽  
Living With Hiv

Emerging prevalence of fatty liver disease in HIV

2021 ◽  
Vol 16 (1) ◽  
pp. 59-73
Author(s):  
Amreen Dinani ◽  
Ali Khan ◽  
Douglas Dieterich
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Unmet Need ◽  
Hiv Care ◽  
People Living With Hiv ◽  
Nonalcoholic Fatty Liver ◽  
Infected People ◽  
Direct Acting ◽  
Living With Hiv

Fatty liver disease is a growing concern in people living with HIV, the main drivers are alcoholic liver disease and nonalcoholic fatty liver disease. It has shown to negatively impact HIV care continuum and result in notable non-HIV related morbidity and mortality. With the advancement in antiretroviral therapy and effective direct acting antivirals, fatty liver disease is surfacing as the next big challenge in this population like that observed in the general population. This review article summarizes the gravity of these two common diseases in HIV-infected people and aims to sheds light on an unmet need to develop effective methods to identify, screen and manage fatty liver disease in this unique population.

Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV

2019 ◽  
Vol 13 (7) ◽  
pp. 643-650 ◽  
Author(s):  
Nicola Squillace ◽  
Alessandro Soria ◽  
Giorgio Bozzi ◽  
Andrea Gori ◽  
Alessandra Bandera
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
People Living With Hiv ◽  
Nonalcoholic Fatty Liver ◽  
Living With Hiv

scholarly journals Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV

AIDS ◽  
2020 ◽  
Vol 34 (13) ◽  
pp. 1915-1921
Author(s):  
Jovana Milic ◽  
Valentina Menozzi ◽  
Filippo Schepis ◽  
Andrea Malagoli ◽  
Giulia Besutti ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Liver Steatosis ◽  
People Living With Hiv ◽  
Nonalcoholic Fatty Liver ◽  
Living With Hiv

scholarly journals Relationship between Dietary Fatty Acid Intake with Nonalcoholic Fatty Liver Disease and Liver Fibrosis in People with HIV

Nutrients ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 3462
Author(s):  
Cristiane Fonseca de Almeida ◽  
Paula Simplicio da Silva ◽  
Claudia Santos de Aguiar Cardoso ◽  
Nathalia Gorni Moreira ◽  
Julliana Cormack Antunes ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Protective Factor ◽  
Hiv Care ◽  
People Living With Hiv ◽  
Nonalcoholic Fatty Liver ◽  
Total Fat

We aimed to evaluate the relationship between food intake of lipids with nonalcoholic fatty liver disease (NAFLD) and/or liver fibrosis in people living with HIV/AIDS (PLWHA). In this cross-sectional study, transient elastography was used to detect the presence of NAFLD and/or liver fibrosis. The dietary intake of fats and fatty acids (FA) were assessed by two 24 h dietary recalls (24-HDR) (n = 451). Multivariate logistic regression models were performed. Participants with higher intake of total fat were associated with higher odds for NAFLD compared to those with lower consumption [adjusted odds ratio (aOR) = 1.91 (95% confidence interval (95% CI) 1.06–3.44)]. Furthermore, participants with intermediate intake of n6-PUFA (n6-poly-unsaturated FA) and lauric FA had lower odds for NAFLD, respectively aOR = 0.54 (95% CI 0.3–0.98) and aOR = 0.42 (95% CI 0.22–0.78). Additionally, a higher intake of myristoleic FA (fourth quartile) was a significant protective factor for NAFLD [aOR = 0.56 (95% CI 0.32–0.99)]. Participants with higher intake of lauric FA [0.38 (95% CI 0.18–0.80)], myristic FA [0.38 (0.17–0.89)], palmitoleic FA [0.40 (0.19–0.82)] and oleic FA [0.35 (0.16–0.79)] had positively less odds of having liver fibrosis. On the other hand, higher intake of n-6 PUFA was significantly associated with fibrosis [aOR = 2.45 (95% CI 1.12–5.32)]. Dietary assessment of total fat and FA should be incorporated into HIV care as a tool for preventing NAFLD and fibrosis in PLWHA.

scholarly journals Features of the course of non-alcoholic fatty liver disease in HIV-infected individuals

2020 ◽  
Vol 47 (2) ◽  
pp. 66-71
Author(s):  
V. A. Akhmedov ◽  
N. F. Mamedova ◽  
A. V. Verbanov ◽  
O. V. Gaus ◽  
O. V. Gaus
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Liver Steatosis ◽  
Experimental Studies ◽  
Rapid Progression ◽  
People Living With Hiv ◽  
Alcoholic Fatty Liver ◽  
High Prevalence ◽  
Alcoholic Fatty Liver Disease

This article reflects the course of non-alcoholic fatty liver disease (NAFLD) in HIV-infected individuals. It is noted that long-term antiretroviral therapy and the use of D-drugs can explain the high prevalence of steatosis in this category of patients. The results of experimental studies that demonstrate the direct effect of HIV on liver steatosis by infection of stellate liver cells, stimulation of abnormal expression of SREBP-1 and PPARγ are considered. The role of HIV-mediated microbial translocation as one of the triggers for the development of non-alcoholic steatohepatitis (NASH), which contributes to chronic inflammation due to an increase in the permeability of the intestinal barrier to bacterial products and endotoxins, is noted. Data are presented confirming the high prevalence of the abnormal distribution of fat and visceral obesity (components of lipodystrophy syndrome) in a cohort of HIV-infected individuals. There was a high prevalence of steatosis and steatohepatitis in HIV-infected patients with lipodystrophy as compared with HIV-infected patients without lipodystrophy. Data showing the high prevalence of NASH in HIV-infected individuals are presented. A high rate of progression of NAFLD in a cohort of HIV-infected individuals was observed, regardless of the presence/absence of a combined viral infection (chronic hepatitis C). It has been established that the classic risk factors for NAFLD (high body mass index, dyslipidemia, metabolic syndrome) can contribute to the rapid progression of the disease in people living with HIV, compared with representatives of the general population.

Prevalence of non-alcoholic fatty liver disease using non-invasive techniques among children, adolescents, and youths living with HIV

AIDS ◽  
2022 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Itzíar Carrasco ◽  
Antonio Olveira ◽  
Ángel Lancharro ◽  
Luis Escosa ◽  
María José Mellado ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Non Invasive ◽  
Invasive Techniques ◽  
Living With Hiv ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease phenotype and prevalence across the menopause spectrum in women living with HIV

2020 ◽  
Vol 73 ◽  
pp. S153-S154
Author(s):  
Jovana Milic ◽  
Adriana Cervo ◽  
Andrea Malagoli ◽  
Denise Morini ◽  
Valentina Menozzi ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Disease Phenotype ◽  
Alcoholic Fatty Liver ◽  
Women Living With Hiv ◽  
Living With Hiv ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document